An endogenous neuropeptide first characterised for inducing delta-wave (slow-wave) sleep, researched for sleep, stress and pain modulation, with mixed results.
Research use only — not approved for human use by FDA or EMA. There is no marketed DSIP drug product.
Also known as: Delta sleep-inducing peptide, DSIP nonapeptide
Acts as a neuromodulator rather than a direct sedative, appearing to normalise dysregulated sleep-wake cycles and increase delta-wave EEG activity. Proposed NMDA-receptor involvement and MAPK interaction; widely distributed in the hypothalamus and limbic system. Its precise receptor remains poorly defined.
DSIP is a naturally occurring nine-amino-acid peptide first isolated from rabbit brain in the 1970s and named for early reports that it promoted delta (slow-wave) sleep. Decades of study have produced mixed and inconsistent results: some studies link it to slow-wave sleep promotion while others show no correlation, and insomnia trials have yielded conflicting outcomes. Its mechanism remains poorly defined. Much of the literature is old, small and never independently replicated. The honest position is that DSIP remains experimental with weak, unreplicated efficacy evidence — its name reflects an early observation, not confirmed clinical efficacy.
We report both positive and negative trial results. For exact study protocols, read the sources — we cite them rather than repackage them.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
High-quality human safety data are essentially absent. Small studies and anecdotal reports suggest some tolerate it without major effects, but standardised long-term safety studies do not exist, so its side-effect profile is uncharacterised.
Discussed alongside sleep-oriented compounds and, in longevity contexts, with Epitalon on a circadian-support rationale. No controlled evidence supports these combinations.
Mechanistic context only — we don't publish combinations, amounts or protocols.
Versus established sleep aids such as benzodiazepine-receptor agonists or melatonin, DSIP lacks both a clear mechanism and consistent efficacy data, so unlike those agents it cannot be considered a validated sleep therapy.
No. After decades of study the evidence is mixed and inconsistent, with some trials showing no effect.
No. It remains experimental and is not approved or validated for insomnia.
No. The name reflects an early observation, not confirmed, replicated clinical efficacy.
No reviews yet. If you've used DSIP, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.